Bio-Techne Corp (TECH) has been under notable market scrutiny due to perceived weakness in stock and sub-par Q4 performance. Despite these financial uncertainties, TECH has fostered remarkable strides in its ongoing developments. The firm recently announced leadership transitions including appointments of Will Geist as president of the protein sciences segment and Kim Kelderman as CEO. Multiple advancements like top-line biomarker data from partner, Regulus, have put TECH in the limelight. TECH's market value defies the declining stock trend with shares being valued 32% over their intrinsic rate. In another remarkable milestone, TECH surpassed 10,000 peer-reviewed publications citing RNAscope technology. Partnerships have been announced with well-established companies such as Nikon Instruments and Thermo Fisher Scientific. New diagnostic tests have received European IVDR certification, point-of-care ocular biomarker assays have been introduced and multiple applications of the MauriceFlex™ System have been highlighted. TECH's stock continues to be an attractive prospect for investors like PNC Financial Services Group, First Trust Advisors among others. However, TECH's acquisition of Lunaphore and investment in Wilson Wolf were two notable events signaling its continued expansion.
Bio-Techne Corp TECH News Analytics from Thu, 07 Jun 2018 07:00:00 GMT to Thu, 27 Jun 2024 11:05:55 GMT -
Rating 6
- Innovation 8
- Information 8
- Rumor -2
